Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-525 gene therapy in severe hemophilia A
NCT03061201Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2017
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of giroctocogene fitelparvovec in hemophilia A, sponsored by Pfizer. Started Jun 2017; status: completed.
02
Drugs
giroctocogene fitelparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03061201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061201.